GLP-1 drugs for obesity and weight loss, which have shown to be extremely effective, are currently one of the most profitable and exciting trends in the market today. The market has been dominated by pharmaceutical giants Eli Lilly ((LLY) and Novo Nordisk ((NVO). However, I see significant opportunities for less mature companies like Hims & Hers Health to get involved. Hims & Hers Health (HIMS) already boasts a Zacks Rank #1 (Strong Buy) rating, reflecting the significant upward revisions to its earnings. H ...